Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
JAMA dermatologyNov 2024
Description
Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
